Back to User profile » Prof. Dr. Hugo A Katus
Papers published by Prof. Dr. Hugo A Katus:
Trigger-Specific Remodeling of KCa2 Potassium Channels in Models of Atrial Fibrillation
Rahm AK, Gramlich D, Wieder T, Müller ME, Schoeffel A, El Tahry FA, Most P, Heimberger T, Sandke S, Weis T, Ullrich ND, Korff T, Lugenbiel P, Katus HA, Thomas D
Pharmacogenomics and Personalized Medicine 2021, 14:579-590
Published Date: 20 May 2021
COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Darche FF, Thomas D, Bruckner T, Katus HA, Ehlermann P, Doesch AO
Clinical Epidemiology 2018, 10:1359-1369
Published Date: 27 September 2018
Short vs prolonged dual antiplatelet treatment upon endovascular stenting of peripheral arteries
Kronlage M, Wassmann M, Vogel B, Müller OJ, Blessing E, Katus H, Erbel C
Drug Design, Development and Therapy 2017, 11:2937-2945
Published Date: 6 October 2017
Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation
Rivinius R, Helmschrott M, Ruhparwar A, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2017, 11:1827-1837
Published Date: 19 June 2017
Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy
Helmschrott M, Rivinius R, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2017, 11:1673-1680
Published Date: 7 June 2017
A comparative study on endovascular treatment of (sub)acute critical limb ischemia: mechanical thrombectomy vs thrombolysis
Kronlage M, Printz I, Vogel B, Blessing E, Müller OJ, Katus HA, Erbel C
Drug Design, Development and Therapy 2017, 11:1233-1241
Published Date: 18 April 2017
The influence of surgical technique on early posttransplant atrial fibrillation — comparison of biatrial, bicaval, and total orthotopic heart transplantation
Rivinius R, Helmschrott M, Ruhparwar A, Erbel C, Gleissner CA, Darche FF, Thomas D, Bruckner T, Katus HA, Doesch AO
Therapeutics and Clinical Risk Management 2017, 13:287-297
Published Date: 8 March 2017
Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis
Preusch MR, Rusnak J, Staudacher K, Mogler C, Uhlmann L, Sievers P, Bea F, Katus HA, Blessing E, Staudacher I
Drug Design, Development and Therapy 2016, 10:2691-2699
Published Date: 26 August 2016
Long-term use of amiodarone before heart transplantation significantly reduces early post-transplant atrial fibrillation and is not associated with increased mortality after heart transplantation
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Schweizer PA, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2016, 10:677-686
Published Date: 16 February 2016
Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study
aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, Katus HA, Kristen AV
Drug Design, Development and Therapy 2015, 9:6319-6325
Published Date: 4 December 2015
Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis
Sievers P, Uhlmann L, Korkmaz-Icöz S, Fastner C, Bea F, Blessing E, Katus HA, Preusch MR
Drug Design, Development and Therapy 2015, 9:3935-3942
Published Date: 29 July 2015
Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation
Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2015, 9:1217-1224
Published Date: 24 February 2015
Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related gene channels: mode of action
Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, Katus HA, Scholz EP,
Drug Design, Development and Therapy 2015, 9:867-877
Published Date: 16 February 2015
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2015, 9:93-102
Published Date: 17 December 2014
CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions
Akhavanpoor M, Gleissner CA, Gorbatsch S, Doesch AO, Akhavanpoor H, Wangler S, Jahn F, Lasitschka F, Katus HA, Erbel C
Drug Design, Development and Therapy 2014, 8:2359-2371
Published Date: 27 November 2014
Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action
Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, Katus HA, Scholz EP
Drug Design, Development and Therapy 2014, 8:2263-2271
Published Date: 7 November 2014
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen
Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2014, 8:1307-1314
Published Date: 9 September 2014
Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions
Doesch AO, Zhao L, Gleissner CA, Akhavanpoor M, Rohde D, Okuyucu D, Hakimi M, Dengler TJ, Katus HA, Erbel C
Drug Design, Development and Therapy 2014, 8:447-457
Published Date: 12 May 2014
Conversion to generic cyclosporine A in stable chronic patients after heart transplantation
Kraeuter M, Helmschrott M, Erbel C, Gleissner CA, Frankenstein L, Schmack B, Ruhparwar A, Ehlermann P, Katus HA, Doesch AO
Drug Design, Development and Therapy 2013, 7:1421-1426
Published Date: 28 November 2013
Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study
Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA
Drug Design, Development and Therapy 2013, 7:1323-1328
Published Date: 5 November 2013
Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation
Doesch AO, Mueller S, Akyol C, Erbel C, Frankenstein L, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA
Drug Design, Development and Therapy 2013, 7:1253-1258
Published Date: 21 October 2013
Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation
Gueler I, Mueller S, Helmschrott M, Oeing CU, Erbel C, Frankenstein L, Gleissner C, Ruhparwar A, Ehlermann P, Dengler TJ, Katus HA, Doesch AO
Drug Design, Development and Therapy 2013, 7:297-303
Published Date: 8 April 2013
Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
Doesch AO, Repp J, Hofmann N, Erbel C, Frankenstein L, Gleissner CA, Schmidt C, Ruhparwar A, Zugck C, Schnitzler P, Ehlermann P, Dengler TJ, Katus HA
Drug Design, Development and Therapy 2012, 6:289-295
Published Date: 12 October 2012
The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation
Schmidt C, Kisselbach J, Schweizer PA, Katus HA, Thomas D
Vascular Health and Risk Management 2011, 7:193-202
Published Date: 31 March 2011